Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
  2. TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
  3. ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
  4. CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
  5. ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study

Latest Content

Summit Therapeutics ends dosing in PhaseOut DMD trial

Summit Therapeutics has completed patient dosing in the PhaseOut DMD clinical trial, a Phase II study of ezutromid to treat patients with duchenne muscular dystrophy (DMD), the most common and severe form of muscular dystrophy.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top